Peak Retirement Planning Inc. Purchases New Position in Exelixis, Inc. $EXEL

Peak Retirement Planning Inc. purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, HoldingsChannel reports. The fund purchased 56,475 shares of the biotechnology company’s stock, valued at approximately $2,332,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after acquiring an additional 19,407 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after purchasing an additional 68,133 shares in the last quarter. Focus Partners Wealth grew its stake in Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. grew its stake in Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the period. Finally, Sivia Capital Partners LLC raised its holdings in Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total value of $4,355,000.00. Following the completion of the transaction, the director owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. The trade was a 7.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Dana Aftab sold 48,383 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the sale, the executive vice president directly owned 664,778 shares in the company, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 245,235 shares of company stock valued at $10,490,600. Company insiders own 2.82% of the company’s stock.

Exelixis Stock Up 3.5%

Shares of EXEL opened at $42.81 on Tuesday. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The company has a market capitalization of $11.48 billion, a P/E ratio of 18.06, a price-to-earnings-growth ratio of 0.75 and a beta of 0.40. The firm has a 50 day moving average of $43.77 and a 200 day moving average of $41.00.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company’s revenue was up 10.8% compared to the same quarter last year. During the same period last year, the business posted $0.47 EPS. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EXEL shares. Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Morgan Stanley boosted their price objective on shares of Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Monday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Finally, Wolfe Research started coverage on Exelixis in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Eleven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Exelixis currently has an average rating of “Hold” and a consensus target price of $46.00.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.